Mirati Therapeutics, Inc.
MRTXDrugs in Pipeline
14
Phase 3 Programs
7
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
MRTX849 Phase 2 Est. Readout
Primary completion for MRTX849 trial (NCT05578092) in Solid Tumor
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
MRTX849
Advanced Cancer
Docetaxel
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Adagrasib
Carcinoma, Non-Small-Cell Lung
Pembrolizumab
Advanced Non-Small Cell Lung Cancer
Cetuximab
Advanced Colorectal Cancer
Enfortumab Vedotin-Ejfv
Advanced or Metastatic Solid Malignancies
Sitravatinib
Clear Cell Renal Cell Carcinoma
Pemetrexed
Solid Tumors
Adagrasib oral dose of 400 mg twice daily tablets
Advanced NSCLC
MGCD265
Non-Small Cell Lung Cancer
Gemcitabine
Tumors
MRTX0902
Solid Tumor
Mocetinostat
Myelodysplastic Syndrome
MGCD0103
Lymphocytic Leukemia, Chronic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MRTX849 | Phase 3 | Advanced Cancer | - | - |
Docetaxel | Phase 3 | Metastatic Non-Squamous Non-Small Cell Lung Cancer | - | - |
Adagrasib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pembrolizumab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
Cetuximab | Phase 3 | Advanced Colorectal Cancer | - | - |
Enfortumab Vedotin-Ejfv | Phase 3 | Advanced or Metastatic Solid Malignancies | - | - |
Sitravatinib | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
Pemetrexed | Phase 2 | Solid Tumors | - | - |
Adagrasib oral dose of 400 mg twice daily tablets | Phase 2 | Advanced NSCLC | - | - |
MGCD265 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Gemcitabine | Phase 2 | Tumors | - | - |
MRTX0902 | Phase 2 | Solid Tumor | - | - |
Mocetinostat | Phase 2 | Myelodysplastic Syndrome | - | - |
MGCD0103 | Phase 2 | Lymphocytic Leukemia, Chronic | - | - |